Ocrelizumab is a medication used for the treatment of multiple sclerosis (MS) and certain types of cancer. It is a monoclonal antibody that targets specific proteins involved in the immune system. In order to protect the intellectual property of this drug, patents have been filed.

According to the sources provided, the specific patents protecting Ocrelizumab are not mentioned. However, it is important to note that patent information is subject to change and may not always be publicly available. It is possible that the information regarding Ocrelizumab's patents is not accessible through the sources provided.

To obtain the most up-to-date and accurate information on the patents protecting Ocrelizumab, it is recommended to consult official patent databases such as the United States Patent and Trademark Office (USPTO) or the European Patent Office (EPO). These databases provide comprehensive information on patents filed for various drugs and can provide detailed information on the patents protecting Ocrelizumab.

In conclusion, while the specific patents protecting Ocrelizumab are not mentioned in the provided sources, further research using official patent databases can provide the most accurate and up-to-date information on the patents protecting this medication.

Sources:
[1] Drug Patent Watch: https://www.drugpatentwatch.com/p/biologics/ingredient/Ocrelizumab
[2] Guide to Pharmacology: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7580
[3] Multiple Sclerosis International Federation: https://www.msif.org/wp-content/uploads/2022/11/2022.11.03_MS-treatments_-patent-overview_new-submission_changes-accepted.docx